



(11) **EP 3 256 147 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 38/18 ^(2006.01) **A61K 47/12** ^(2006.01)

(86) International application number:
PCT/US2016/013564

(48) Corrigendum issued on:
21.10.2020 Bulletin 2020/43

(87) International publication number:
WO 2016/115442 (21.07.2016 Gazette 2016/29)

(45) Date of publication and mention
of the grant of the patent:
05.08.2020 Bulletin 2020/32

(21) Application number: **16703658.1**

(22) Date of filing: **15.01.2016**

(54) **THERAPEUTIC PROTEIN FORMULATIONS**
THERAPEUTISCHE PROTEINFORMULIERUNGEN
FORMULATIONS DE PROTÉINES THÉRAPEUTIQUES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **18.01.2015 US 201562104804 P**

(43) Date of publication of application:
20.12.2017 Bulletin 2017/51

(60) Divisional application:
20189324.5
20189367.4

(73) Proprietor: **Gloriana Therapeutics, Inc.**
Rhode Island, RI 02885 (US)

(72) Inventor: **DIMITROVA, Mariana**
Medford, Massachusetts 02155 (US)

(74) Representative: **Grund, Martin**
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München (DE)

(56) References cited:
WO-A1-02/052433 WO-A1-2008/137574
WO-A1-2012/138958 WO-A2-00/01815
WO-A2-02/078730 WO-A2-2007/103182

- **SYDNEY O UGWU ET AL: "The effect of buffers on protein conformational stability", PHARMACEUTICAL TECHNOLOGY, vol. 28, no. 3, 1 March 2004 (2004-03-01), page 86, XP055259995, US ISSN: 1543-2521**
- **"Data Sheet Growth AGGPGSRARA AGARGCRLRS QLVPVRALGL GHRSDLVRF RFCSGSCRRA RSPHDLASLLGAGALRPP PGSRPVSQPC CRPTRYEAVS FMDVNSTWRT VDRLSATACG CLG", , 3 January 2011 (2011-01-03), XP055263182, Retrieved from the Internet: URL: http://www.cellgs.com/Downloads/1002/datasheet_artemin_human.pdf [retrieved on 2016-04-06]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 256 147 B8